Document Detail


Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
MedLine Citation:
PMID:  3276299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty parkinsonian patients (Hoehn and Yahr scale, I through III) were treated with controlled-release carbidopa-levodopa (CR-2 or CR-3) and standard carbidopa-levodopa (Sinemet, 25 mg/100 mg) in a double-blind, crossover pharmacokinetic and clinical efficacy study. The controlled-release agents had a slower rise to peak plasma values and flatter pharmacokinetic curves than did the standard. The area under the curve for CR-3 was significantly increased by 55.5% as compared with standard agent and by 84.2% as compared with CR-2. No differences in clinical efficacy were found between controlled-release agents and the standard agent for this group of parkinsonian patients with mild to moderate severity. The dissociation between the prolonged serum levodopa levels and unimproved clinical efficacy may have resulted from the absence of patients with prominent motor fluctuations and/or substantial serum levodopa variability that was especially prominent with CR-3.
Authors:
J T Hutton; J W Albrecht; G C Román; M T Kopetzky
Related Documents :
1447729 - Acoustic analysis in the differentiation of parkinson's disease and major depression.
22448309 - Should we look for celiac disease among all patients with liver function test abnormali...
12809999 - Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents.
18175339 - Voluntary, spontaneous, and reflex blinking in parkinson's disease.
20199199 - Eeg evidence of posterior cortical disconnection in pd and related dementias.
7059869 - Adverse neurologic effects of metoclopramide.
3267489 - Abnormalities of visual evoked responses in hyperprolactinaemia.
10894879 - Phase i and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysf...
14596359 - Risk factor profile and achievement of treatment goals among hypertensive patients from...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Archives of neurology     Volume:  45     ISSN:  0003-9942     ISO Abbreviation:  Arch. Neurol.     Publication Date:  1988 Jan 
Date Detail:
Created Date:  1988-01-27     Completed Date:  1988-01-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372436     Medline TA:  Arch Neurol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  55-7     Citation Subset:  AIM; IM    
Affiliation:
Department of Medical and Surgical Neurology, Texas Tech University Health Sciences Center, Lubbock 79430.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Carbidopa / administration & dosage*,  pharmacokinetics
Clinical Trials as Topic
Delayed-Action Preparations
Double-Blind Method
Drug Combinations
Female
Humans
Levodopa / administration & dosage,  blood*,  pharmacokinetics
Male
Middle Aged
Parkinson Disease / blood*,  drug therapy
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Drug Combinations; 0/Levodopa; 38821-49-7/Carbidopa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis.
Next Document:  Rezsö Bálint and his most celebrated case.